⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AARD News
Aardvark Therapeutics, Inc. Common Stock
AARD DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
accessnewswire.com
AARD
Pomerantz Law Firm Announces The Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
accessnewswire.com
AARD
Form 8-K
sec.gov
AARD
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
AARD
Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman
prnewswire.com
AARD
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower – Hagens Berman
globenewswire.com
AARD
Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman
prnewswire.com
AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
prnewswire.com
AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
prnewswire.com
AARD